CS276439B6 - Pharmaceutical for treating auto-immune diseases - Google Patents
Pharmaceutical for treating auto-immune diseases Download PDFInfo
- Publication number
- CS276439B6 CS276439B6 CS902689A CS268990A CS276439B6 CS 276439 B6 CS276439 B6 CS 276439B6 CS 902689 A CS902689 A CS 902689A CS 268990 A CS268990 A CS 268990A CS 276439 B6 CS276439 B6 CS 276439B6
- Authority
- CS
- Czechoslovakia
- Prior art keywords
- animals
- cells
- group
- proteoglycan
- carbon atoms
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE3918082A DE3918082A1 (de) | 1989-06-02 | 1989-06-02 | Mittel gegen autoimmunerkrankungen |
Publications (2)
Publication Number | Publication Date |
---|---|
CS268990A3 CS268990A3 (en) | 1992-01-15 |
CS276439B6 true CS276439B6 (en) | 1992-05-13 |
Family
ID=6381972
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CS902689A CS276439B6 (en) | 1989-06-02 | 1990-05-31 | Pharmaceutical for treating auto-immune diseases |
Country Status (14)
Country | Link |
---|---|
US (1) | US5266564A (da) |
EP (1) | EP0474712B1 (da) |
JP (1) | JP2977894B2 (da) |
AT (1) | ATE94757T1 (da) |
AU (1) | AU5670690A (da) |
CA (1) | CA2056421C (da) |
CS (1) | CS276439B6 (da) |
DE (2) | DE3918082A1 (da) |
DK (1) | DK0474712T3 (da) |
ES (1) | ES2060173T3 (da) |
GR (1) | GR1001195B (da) |
IE (1) | IE64039B1 (da) |
WO (1) | WO1990014829A1 (da) |
ZA (1) | ZA904196B (da) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3941009A1 (de) * | 1989-12-12 | 1991-06-13 | Medmark Pharma Gmbh | Eliminierung von aktivierten lymphozyten |
HU230515B1 (hu) * | 1996-02-09 | 2016-10-28 | Abbvie Biotechnology Ltd | Humán TNFalfa-kötő antitestek alkalmazásai |
US6583127B1 (en) | 1998-12-21 | 2003-06-24 | Inkeysa. Sa | Use of etherlysophospholipids as antiinflammatory agents |
SE9902155L (sv) * | 1999-06-09 | 2000-12-10 | Bjoern Rydevik | Serum antibodies |
JP2002228764A (ja) * | 2001-02-02 | 2002-08-14 | Fuji Photo Film Co Ltd | 透光性シート体検出装置 |
DK2089711T3 (da) | 2006-11-10 | 2012-11-26 | Alphaptose Gmbh | Fremgangsmåder og sammensætninger til detektion af receptor-ligand-mimetika |
ATE546133T1 (de) * | 2006-11-10 | 2012-03-15 | Alphaptose Gmbh | Orale dosierform mit trisubstituierten glycerin- verbindungen |
ES2391659T3 (es) * | 2006-11-10 | 2012-11-28 | Radioprotect Alphaptose Ug(Haftungsbeschränkt) & Co. Kg | Uso de compuestos de glicerol trisustituido para el tratamiento de lesiones por radiación |
WO2008074573A1 (en) * | 2006-12-20 | 2008-06-26 | Alphaptose Gmbh | Topical dosage form comprising tri-substituted glycerol compounds |
US8697138B2 (en) | 2007-03-28 | 2014-04-15 | Aker Biomarine As | Methods of using krill oil to treat risk factors for cardiovascular, metabolic, and inflammatory disorders |
EP2612672A1 (en) | 2007-03-28 | 2013-07-10 | Aker BioMarine AS | Bioeffective krill oil compositions |
US20100226977A1 (en) * | 2007-08-29 | 2010-09-09 | Aker Biomarine Asa | Low viscosity phospholipid compositions |
KR101192880B1 (ko) * | 2007-08-29 | 2012-10-18 | 에이커 바이오마린 에이에스에이 | 새로운 크릴 밀 제조 방법 |
US8372812B2 (en) * | 2009-02-26 | 2013-02-12 | Aker Biomarine Asa | Phospholipid and protein tablets |
WO2013156630A1 (en) | 2012-04-20 | 2013-10-24 | Alphaptose Gmbh | S-enantiomer of a tri-substituted glycerol compound |
AU2014203179C1 (en) | 2013-06-14 | 2017-05-04 | Aker Biomarine Antarctic As | Lipid extraction processes |
GB201400431D0 (en) | 2014-01-10 | 2014-02-26 | Aker Biomarine As | Phospholipid compositions and their preparation |
PT3256003T (pt) | 2015-02-11 | 2023-02-15 | Aker Biomarine Antarctic As | Processo de extração de lipídios |
EP3256553A2 (en) | 2015-02-11 | 2017-12-20 | Aker Biomarine Antarctic AS | Lipid compositions |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2009342C3 (de) * | 1970-02-27 | 1980-12-18 | Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V., 3400 Goettingen | Verwendung von Glycerin-alkyläther-(l)-phosphorsäure-(3)-monocholinestern |
DE2009343C3 (de) * | 1970-02-27 | 1980-10-23 | Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V., 3400 Goettingen | Verwendung von Lysolecithinen als immunologische Adjuvantien |
DE2619686C2 (de) * | 1976-05-04 | 1986-08-07 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., 3400 Göttingen | Verwendung eines Lysolecithins zur Tumorbehandlung |
CH670763A5 (da) * | 1985-08-02 | 1989-07-14 | Seuref Ag | |
DE3530767A1 (de) * | 1985-08-28 | 1987-03-12 | Max Planck Gesellschaft | Mittel gegen multiple sklerose |
-
1989
- 1989-06-02 DE DE3918082A patent/DE3918082A1/de active Granted
-
1990
- 1990-05-29 GR GR900100406A patent/GR1001195B/el not_active IP Right Cessation
- 1990-05-31 CS CS902689A patent/CS276439B6/cs not_active IP Right Cessation
- 1990-05-31 JP JP2507957A patent/JP2977894B2/ja not_active Expired - Fee Related
- 1990-05-31 US US07/777,248 patent/US5266564A/en not_active Expired - Lifetime
- 1990-05-31 AU AU56706/90A patent/AU5670690A/en not_active Abandoned
- 1990-05-31 CA CA002056421A patent/CA2056421C/en not_active Expired - Fee Related
- 1990-05-31 EP EP90908504A patent/EP0474712B1/de not_active Expired - Lifetime
- 1990-05-31 ES ES90908504T patent/ES2060173T3/es not_active Expired - Lifetime
- 1990-05-31 AT AT90908504T patent/ATE94757T1/de not_active IP Right Cessation
- 1990-05-31 WO PCT/EP1990/000870 patent/WO1990014829A1/de active IP Right Grant
- 1990-05-31 DK DK90908504.5T patent/DK0474712T3/da active
- 1990-05-31 DE DE90908504T patent/DE59002863D1/de not_active Expired - Fee Related
- 1990-06-01 IE IE198790A patent/IE64039B1/en not_active IP Right Cessation
- 1990-06-01 ZA ZA904196A patent/ZA904196B/xx unknown
Also Published As
Publication number | Publication date |
---|---|
DK0474712T3 (da) | 1993-11-29 |
WO1990014829A1 (de) | 1990-12-13 |
CA2056421C (en) | 2000-10-10 |
JP2977894B2 (ja) | 1999-11-15 |
GR900100406A (en) | 1991-11-15 |
EP0474712A1 (de) | 1992-03-18 |
ES2060173T3 (es) | 1994-11-16 |
EP0474712B1 (de) | 1993-09-22 |
IE64039B1 (en) | 1995-06-28 |
CA2056421A1 (en) | 1990-12-03 |
DE3918082A1 (de) | 1991-01-24 |
AU5670690A (en) | 1991-01-07 |
DE59002863D1 (de) | 1993-10-28 |
US5266564A (en) | 1993-11-30 |
ATE94757T1 (de) | 1993-10-15 |
GR1001195B (el) | 1993-06-07 |
CS268990A3 (en) | 1992-01-15 |
IE901987L (en) | 1990-12-02 |
DE3918082C2 (da) | 1992-02-06 |
ZA904196B (en) | 1991-03-27 |
JPH04507096A (ja) | 1992-12-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CS276439B6 (en) | Pharmaceutical for treating auto-immune diseases | |
Macdermott et al. | Alterations of the immune system in ulcerative colitis and Crohn's disease | |
Wofsy et al. | Reversal of advanced murine lupus in NZB/NZW F1 mice by treatment with monoclonal antibody to L3T4. | |
Skelly et al. | Making sense of the schistosome surface | |
Kita et al. | Probucol prevents the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbit, an animal model for familial hypercholesterolemia. | |
Voorthuis et al. | Suppression of experimental allergic encephalomyelitis by intraventricular administration of interferon‐gamma in Lewis rats | |
Jain et al. | Contribution of Porphyromonas gingivalis lipopolysachharide to periodontitis | |
Harvey | Cytolytic toxins | |
Winn et al. | Acute destruction by humoral antibody of rat skin grafted to mice: the role of complement and polymorphonuclear leukocytes | |
Fallon et al. | Immune-dependent chemotherapy of schistosomiasis | |
EP0251134B1 (en) | Compositions for preventing graft rejection | |
US7608246B2 (en) | Apolipoprotein E as an adjuvant for lipid antigens | |
AU665764B2 (en) | Methods and compositions for the prevention, diagnosis, and treatment of inflammatory serosal disease and related conditions | |
Seil | Demyelination | |
RU2083210C1 (ru) | Средство для профилактической, поддерживающей и восстановительной терапии развивающихся при старении и/или под воздействием патогенных факторов патологий, связанных с дистрофическим и дегенеративными изменениями органов и тканей | |
RAMSEY et al. | Chemotaxis | |
Bräuer et al. | Changes of immunoregulatory properties and induction of autoimmune reactivity to cartilage in rabbits with antigen-induced arthritis | |
Internationalis | Bacteriology, immunology | |
Du Clos | THE SUPPRESSOR CELL IN NEONATALLY INDUCED TOLERANCE. | |
SKOPISKA | Effect of lipopolysaccharide on the development of cell-mediated immunity to transplantation antigens | |
Ginsburg et al. | Bayer-Symposium VI, Experimental Models of Chronic Inflammatory Diseases, 256-299 (1977) by Springer-Verlag 1977 Experimental Models of Streptococcal Arthritis: Pathogenetic Role of Streptococcal Products and | |
Smiley | The immune response in rheumatoid synovitis | |
Weltzin | Intracellular Calcium and Protein Kinase C Regulate Nonspecific Cell-Mediated Cytotoxicity by Mouse Lymphocytes (Calmodulin) | |
Hill | Role of Invariant Natural Killer T Cells in Tularemia-like Disease in Mice | |
Li | Molecular mechanisms controlling NF-κB activation in rheumatoid arthritis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
IF00 | In force as of 2000-06-30 in czech republic | ||
MM4A | Patent lapsed due to non-payment of fee |
Effective date: 20080531 |